OXIS INTERNATIONAL, INC. (OTCMKTS:OXIS) Files An 8-K Unregistered Sales of Equity Securities

OXIS INTERNATIONAL, INC. (OTCMKTS:OXIS) Files An 8-K Unregistered Sales of Equity Securities
ITEM 3.02 Unregistered Sales of Equity Securities.

The Registrant has issued a total of 42,263,842 shares of common stock (the “Shares”) to a total of four entities or individuals in exchange for the cancellation of debt in the total amount of $482,455 and interest in the total amount of $79,924. The issuance was exempt from the registration requirements of Section 5 of the Securities Act of 1933 to Section 4(2) of the same Act since the issuance of the Shares did not involve any public offering. Following the issuances, the Registrant has a total of 115,215,073 shares of common stock issued and outstanding.


OXIS International, Inc. (OXIS) is an immuno-oncology company. The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. The Company develops drugs focused on the treatment of cancer. Its technology platform consists of bispecific and trispecific single-chain variable fragment (scFv) constructs, full-length antibodies, drug payloads, antibody-drug linkers, dual-drug payload antibody-drug conjugates (ADCs), bispecific targeted ADCs, and natural killer cell and T lymphocyte antibody directed cell-mediated cytotoxic (ADDCs) agents. Its drug candidates include OXS-1550, OXS-2175 and OXS-4235. OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate. OXS-2175 is a small molecule therapeutic candidate for the treatment of triple-negative breast cancer. OXS-4235 is also a small molecule therapeutic candidate, which targets the treatment of multiple myeloma and associated osteolytic lesions.


OXIS INTERNATIONAL, INC. (OTCMKTS:OXIS) closed its last trading session down -0.0021 at 0.0180 with 11,181,197 shares trading hands.

An ad to help with our costs